Research · 8 min read
When estrogen patches are hard to find: how to keep your hormone therapy on track
If your usual estrogen patch is delayed or out of stock, you are not alone, and a gap in treatment is not something to manage on your own. A November 15, 2026, Fort Worth Report story described women who could not consistently fill estrogen-patch prescriptions. One person waited six weeks for a higher-dose patch, though she could still get her original lower dose during that wait. Another, whose twice-weekly patch could not be refilled, went about a month without hormone therapy, noticed symptoms coming back, then tried a once-weekly patch, a gel, and the weekly patch again.
Those are practical access problems, not a reason to stop, stretch, share, or switch hormone therapy without a clinician. In October we published a guide to what FDA has said and what to ask. On November 15 we covered how forms of hormone therapy differ.
Why patches are hard to find—and what "shortage" does and doesn't mean
In an update dated September 3, 2026 (content current as of that date; rechecked November 16, 2026), FDA said it is aware of reports of patients having difficulty readily accessing their usual estradiol transdermal patches due to increased demand, and that it is working with all six manufacturers to increase supply. Availability of certain products or brands may vary by pharmacy or location, FDA said, but estradiol transdermal patches "remain available." Over the last year, the supply of FDA-approved estradiol transdermal patches has "nearly doubled."
In a section titled "Why has demand increased?", FDA says more women have been seeking treatment for menopause symptoms, and that "Demand for these products increased following the November 2025 action by the FDA to request that manufacturers make changes to the labeling to remove boxed warnings about a probable risk of breast cancer, cardiovascular disease, and probable dementia for patients receiving menopausal hormone therapy products for menopause." That is FDA's account, in the wording of its November 2025 request. It is not the same as saying FDA removed most boxed-warning statements from hormone therapy.
The change is product by product. FDA's public list of menopausal hormone therapies with updated prescribing information—content current as of October 30, 2026; rechecked November 16, 2026—names nine products and says only that prescribing information "has been updated." It does not say boxed warnings were removed. We reviewed the nine current labels on November 15, 2026. On the systemic estrogen-alone products on the list (Divigel, Cenestin, Enjuvia, Minivelle (ASHP reports the brand was discontinued in February and still lists an authorized generic from Noven), Vivelle, and Vivelle-Dot), a boxed warning about endometrial cancer with unopposed estrogen remains. On Bijuva, an estradiol-plus-progesterone capsule indicated for women with a uterus, the boxed warning was removed. The current Prometrium and Estring labels we read do not include a boxed warning. Some versions published elsewhere, including on DailyMed, may lag. "Removed from the boxed warning" is not "no risks." For systemic products, FDA asked that cardiovascular disease and breast cancer warnings remain in the labeling. See our boxed-warning explainer and who should not take hormone therapy.
Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus.
As of November 16, 2026, FDA's Drug Shortages database does not list estradiol transdermal patches among current shortages, resolved shortages, or discontinuations. FDA has not declared an official shortage. The American Society of Health-System Pharmacists (ASHP) does currently list estradiol transdermal systems as a shortage; its bulletin, updated November 4, 2026, reports some brands and strengths on back order or allocation and others as available. An ASHP listing is not an FDA shortage designation. Neither list means every pharmacy has—or lacks—every brand and strength.
What to do if you cannot fill your patch
Call your pharmacist, and call ahead when you can. If you are having trouble finding your usual estradiol transdermal patch, FDA says your pharmacist can check availability and "may be able to help locate another available FDA-approved estradiol transdermal patch that can be substituted for your current product, when appropriate." Strength and schedule—twice-weekly versus once-weekly—both matter.
Talk with your clinician about a different patch schedule, or another approved patch, if your usual one is not available. Those are not automatically the same prescription. In the Fort Worth Report account, a person whose twice-weekly patch could not be refilled later used a once-weekly patch. Whether that change is appropriate for you belongs in a visit.
Ask about the once-weekly generic combination patch—and know what it is not. In a news release dated October 20, 2026, FDA said it had approved, on October 19, 2026, the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a once-weekly transdermal hormone therapy patch for women with an intact uterus. FDA says the generic is therapeutically equivalent to Climara Pro, which is indicated, in women with an intact uterus, for treatment of moderate to severe vasomotor symptoms due to menopause and for prevention of postmenopausal osteoporosis. Both products contain estrogen and progestogen in a single patch, which FDA notes differs from estrogen-only patches commonly used in menopause treatment; they are specifically approved for women with an intact uterus because the progestogen is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone. FDA approved Zydus Pharmaceuticals (USA) Inc.'s Estradiol and Levonorgestrel Transdermal System and said to contact the manufacturer for information about availability. Approval is not the same as a patch already on the shelf, and a combination product is not a simple swap for an estrogen-only patch. Naming a product does not mean Kindr Health prescribes it. The same release lists contraindications and the most common adverse reactions; read those with your clinician.
Consider a gel or another route only with your clinician. A gel, a spray, or a pill can be an option when a patch cannot be filled. It is not a do-it-yourself substitution. If you have a uterus and you use systemic estrogen, you typically still need a progestogen.
Talk with your clinician or pharmacist before stopping or changing your medication, and do not improvise a dose. FDA says: "Do not stop or change your medication without talking with your healthcare provider." If you cannot obtain your usual medication, contact your clinician. Symptoms may come back if there is a gap; the Fort Worth Report described brain fog, itchiness, and not feeling like oneself after about a month without therapy. Do not cut, split, reuse, or stretch patches, and do not share prescription hormone therapy. ASHP notes that cutting a patch can release the dose unevenly. FDA also suggests checking back with your pharmacy.
What switching routes means in practice
A patch, a gel, a spray, and a pill can all deliver estrogen, but they are used differently. We do not list dosing equivalents: a milligram on one product is not automatically the same as a milligram on another. Any change of dose, brand, schedule, or route should be made with your clinician. A twice-weekly patch is changed more often than a once-weekly patch. A gel is usually applied more often than either, which can be easier to forget. A patch can irritate the skin or fail to stay on. A combination once-weekly patch already includes a progestogen and is approved for women with a uterus; an estrogen-only patch is a different product. Low-dose vaginal estrogen is for local genitourinary symptoms such as vaginal dryness; it is not a substitute for systemic therapy for hot flashes. We discussed research on estrogen type and route, and its limits, in our November 15 post.
How a new ACOG guideline fits
On October 15, 2026, the American College of Obstetricians and Gynecologists (ACOG) published Clinical Practice Guideline 13, "Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms," replacing Practice Bulletin 141. ACOG's news release calls it the most comprehensive menopause guidance the organization has published to date, covering treatment options for vasomotor symptoms (hot flashes and night sweats), sleep, and mood changes.
ACOG recommends that initiating hormone therapy be based on shared decision-making, considering the patient's symptoms; the benefits and risks of therapy based on age, medical history, and baseline risks of cardiovascular disease, breast cancer, and venous thromboembolism; and individualized treatment goals and priorities. If hormone therapy is selected, ACOG recommends starting it before age 60 or within 10 years of the start of spontaneous menopause, in people without contraindications. Decisions about when and how to discontinue therapy should also be individualized. The release says the guidance includes more detail on hormone-therapy options for vasomotor symptoms and vasomotor-related sleep disturbances. The release also describes nonhormonal options, including SSRIs and SNRIs, which it says can help manage hot flashes and depression; it does not describe hormone therapy as a recommended treatment for menopause-related depression. We summarized the document in an earlier post.
Where Kindr fits
At Kindr Health, menopause and midlife care is clinician-led. If a patch is delayed or unavailable, a licensed clinician can talk through whether another FDA-approved patch, a different schedule, or another route is appropriate. Kindr Care patient intake is open now.
This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.
Sources
- McKinnon Rice, "Fort Worth women face challenges in filling estrogen patch prescriptions. They're not alone," Fort Worth Report, November 15, 2026 — fortworthreport.org/2026/11/15/fort-worth-women-face-challenges-in-filling-estrogen-patch-prescriptions-theyre-not-alone
- FDA, "FDA Update on Estradiol Transdermal Patch Availability" (September 3, 2026; content current as of September 3, 2026; rechecked November 16, 2026) — www.fda.gov/drugs/drug-alerts-and-statements/fda-update-estradiol-transdermal-patch-availability
- FDA Drug Shortages database (checked November 16, 2026) — dps.fda.gov/drugshortages
- ASHP, Drug Shortage Detail: Estradiol Transdermal System (created January 30, 2026; updated November 4, 2026; checked November 16, 2026) — www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1206
- FDA, "FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women" (October 20, 2026) — www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women
- FDA, Menopausal Hormone Therapies with Updated Prescribing Information (content current as of October 30, 2026; rechecked November 16, 2026) — www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
- FDA, Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies (November 10, 2025; content current as of February 12, 2026) — www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
- Current FDA labels for the nine products on the updated-prescribing-information list, linked from the FDA list page above and reviewed November 15, 2026 (list page unchanged on November 16, 2026) — www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
- ACOG, Clinical Practice Guideline 13, "Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms" (public guideline page) — www.acog.org/clinical/guidance/clinical-practice-guideline/2026/11/management-of-menopause-related-vasomotor-sleep-and-mood-symptoms
- ACOG, "ACOG Expands Recommendations for Management of Menopause Symptoms," October 15, 2026 — www.acog.org/news/2026/10/acog-expands-recommendations-for-management-of-menopause-symptoms
- Kindr journal: Estrogen Patch Shortage? Keep Menopause Care on Track — kindr.health/journal/estrogen-patch-shortage-what-to-ask
- Kindr journal: Estradiol, conjugated estrogens, patch or pill: does the type of hormone therapy matter? — kindr.health/journal/estradiol-conjugated-estrogens-patch-or-pill
- Kindr journal: "Removed from the boxed warning": what changed—and what it means for you — kindr.health/journal/boxed-warning-removed-what-changed-brain-estrogen
- Kindr journal: Who shouldn't take hormone therapy? Contraindications, gray areas, and your non-hormonal options — kindr.health/journal/who-shouldnt-take-hormone-therapy
- Kindr journal: ACOG issues its most comprehensive menopause guidance yet — kindr.health/journal/acog-expands-menopause-symptom-management-guidance-2026
Medically reviewed by Kindr Health Clinical Team
Last updated: November 16, 2026
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Is HRT safe?Journal
- When to start HRTJournal
- Menopause HRT serviceMedication
- Complete menopause guideJournal
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.